Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Jacqueline S. Garcia, MD, Andrew H. Wei, Uma Borate, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Joseph G. Jurcic, MD, Meagan A. Jacoby, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Ilona Cunningham, MBBS, FRACP, FRCPA, Ying Zhou, PhD, Bo Tong, PhD, Leah Hogdal, PhD, Rajesh Kamalakar, MS, Jessica E. Hutti, PhD, Steve Kye, MD MPH, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 55–57.

https://doi.org/10.1182/blood-2020-139492

Published: 2020

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Blood (2019) 134 (Supplement_1): 565.

https://doi.org/10.1182/blood-2019-124994

Published: 2019

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD

Blood (2019) 134 (Supplement_1): 568.

https://doi.org/10.1182/blood-2019-124437

Published: 2019

Journal Articles

Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Thomas Alexander, MD MPH, Norman J. Lacayo, MD, Vinod A. Pullarkat, MD, Elias J. Jabbour, MD, Seong Lin Khaw, MD, Charles G. Mullighan, MBBS, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Jessica Leonard, MD, Robin Norris, MD, Jeffrey Rubnitz, MD PhD, Susan I. Vear, MD MSCI, Michelle Schmidt, Bo Tong, PhD, Ying Zhou, PhD, Jeremy A. Ross, PhD, Lindsey Rosenwinkel, Amanda Jacobson, PhD, Su Young Kim, MD PhD, Wendy Stock, MD

Blood (2018) 132 (Supplement 1): 3966.

https://doi.org/10.1182/blood-2018-99-113464

Published: 2018

Journal Articles

Autocrine Signaling by Osteopontin Regulates Actin Remodeling in Human Primary Erythroid Progenitors.

Amittha Wickrema, PhD, Ying Zhou, PhD, Jessica Reynolds, MS, Jodie Ulaszek, BS, Nilesh Satgurunathan, Koen van Besien, MD, Jeong-Ah Kang, PhD

Blood (2005) 106 (11): 1667.

https://doi.org/10.1182/blood.V106.11.1667.1667

Published: 2005

NARROW

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Autocrine Signaling by Osteopontin Regulates Actin Remodeling in Human Primary Erythroid Progenitors.

Email alerts

ASH Publications

American Society of Hematology

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Autocrine Signaling by Osteopontin Regulates Actin Remodeling in Human Primary Erythroid Progenitors.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only